• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Big Rock Partners Acquisition Corp.

    5/14/21 5:01:11 PM ET
    $BRPA
    Business Services
    Finance
    Get the next $BRPA alert in real time by email
    NT 10-Q 1 brpa_nt10q.htm PRIMARY DOCUMENT brpa_nt10q
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    OMB APPROVAL
    OMB Number:   3235-0058
    Expires:   February 28, 2022
    Estimated average burden
    Hours per form  2.50
     
    Washington, D.C. 20549
     
    FORM 12b-25
     
    NOTIFICATION OF LATE FILING
    SEC FILE NUMBER
    001-38302
    CUSIP NUMBER
    089482 103
     
     
    (Check One): 
    ☐    Form 10-K     ☐    Form 20-F     ☐    Form 11-K     ☒    Form 10-Q     ☐    Form 10-D     ☐    Form N-CEN     ☐    Form N-CSR
     
    For Period Ended: March 31, 2021
     
    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form N-SAR
     
                            For the Transition Period Ended: __________________                                                                    
     
    Read Instructions (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
     
     
    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A
     
    PART I – REGISTRANT INFORMATION
     
    Big Rock Partners Acquisition Corp.
    Full Name of Registrant
     
    N/A
    Former Name if Applicable
     
    2645 N. Federal Highway, Suite 230                                                                 
    Address of Principal Executive Office (Street and Number)
     
    Delray Beach, FL 33483                                            
    City, State and Zip Code
     
    PART II – RULES 12b-25 (b) AND (c)
     
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
     
     ☒
    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
     

     
    PART III – NARRATIVE
     
    State below in reasonable detail the reasons why the Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed)
     
    Big Rock Partners Acquisition Corp. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (“Form 10-Q”) by the prescribed due date. The Company requires additional time to compile and verify the data required to be included in the Form 10-Q. The Company expects to file the Form 10-Q within the additional time allowed.
     
     
    PART IV – OTHER INFORMATION
     
    (1)
    Name and telephone number of person to contact in regard to this notification
     
     
    Richard Ackerman
    (Name)
    (310)
    (Area Code)
    734-2300
    (Telephone Number)
     
     
    (2)
    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
      Yes     ☒     No    ☐
     
     
    (3)
    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes     ☐     No    ☒
     
     
     
    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
     
     
     
     
     
    BIG ROCK PARTNERS ACQUISITION CORP.
    (Name of Registrant as Specified in Charter)
     
    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
     
     
     
    Date: May 14, 2021
    By:  
    /s/ Richard Ackerman  
     
     
     
    Richard Ackerman
     
     
     
    Chairman, President and Chief Executive Officer
     
     
    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
     
    ATTENTION
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
     
     
     

    Get the next $BRPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRPA
    SEC Filings

    View All

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:36 PM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:03 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/26/21 4:13:58 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: BRAC Lending Group LLC returned 869,565 units of Common Stock to the company, decreasing direct ownership by 60% to 590,435 units (Amendment)

    4/A - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    6/4/21 9:40:44 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 9:17:34 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 8:02:21 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

    RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (NASDAQ:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no curr

    5/25/21 6:48:00 AM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

    Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (NASDAQ:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.Big Rock also announced that the U.S. Securities and Exchange Commission has declared effective its registration state

    5/21/21 6:40:00 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/4/21 10:17:16 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D filed by Big Rock Partners Acquisition Corp.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/3/21 5:30:14 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    5/26/21 5:02:30 PM ET
    $BRPA
    Business Services
    Finance